Abstract
Cannabinoid subtype 1 receptor (CB1R) antagonists were originally developed as anti-obesity agents. Unfortunately, SR1417116A (rimonabant), the first ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
